Online inquiry

IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4235MR)

This product GTTS-WQ4235MR is a type of mRNA modified with Pseudo-UTP, which ecodes the monoclonal antibody that targets Factor VIII substitute gene. The antibody can be applied in Hemophilia A research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000132.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2157
UniProt ID P00451
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4235MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5028MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ8545MR IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Hu5A8
GTTS-WQ7706MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GEXMab73
GTTS-WQ7426MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA GA201
GTTS-WQ4646MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986036
GTTS-WQ1460MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ14466MR IVTScrip™ mRNA-Anti-MAPT, RO-7105705(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RO-7105705
GTTS-WQ14058MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-3918
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW